Literature DB >> 10329560

Activation of Bcl-2 promoter-directed gene expression by the human immunodeficiency virus type-1 Tat protein.

Z Wang1, G F Morris, J C Reed, G D Kelly, C B Morris.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) Tat transcriptionally activates expression from a number of viral and cellular promoters. Recent studies demonstrate the ability of Tat to differentially modulate cellular responses to apoptotic signaling. The antiapoptotic effects of Tat appear to correlate with increased expression of Bcl-2, a cellular protein that enhances cellular survival. Here, endogenous expression of HIV-1 Tat in HeLa and Jurkat cells elevates levels of Bcl-2. Transient expression assays performed in HeLa cells demonstrate that Tat directly or indirectly enhances Bcl-2 promoter-directed gene expression by more than 10-fold. Analyses of Tat mutants demonstrate that two noncontiguous regions in the N- and C-termini of Tat mediate maximal transactivation of the Bcl-2 promoter. The requirement for C-terminal sequences contrasts with transactivation of the HIV-1 long terminal repeat in which the N-terminal 57 amino acids are required but downstream residues are not. Bcl-2 promoter analyses suggest that sequences required for Tat responsiveness are located upstream of P1 and between the P1 and P2 promoter units. Results from these studies reveal effects of HIV-1 Tat on Bcl-2 expression and provide a putative mechanism by which endogenously expressed Tat affects cellular survival through the up-regulation of Bcl-2. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10329560     DOI: 10.1006/viro.1999.9688

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing?

Authors:  R A Arnaout; M A Nowak; D Wodarz
Journal:  Proc Biol Sci       Date:  2000-07-07       Impact factor: 5.349

Review 2.  Using death to one's advantage: HIV modulation of apoptosis.

Authors:  T M Ross
Journal:  Leukemia       Date:  2001-03       Impact factor: 11.528

3.  Maintenance of the HIV Reservoir Is Antagonized by Selective BCL2 Inhibition.

Authors:  Nathan W Cummins; Amy M Sainski-Nguyen; Sekar Natesampillai; Fatma Aboulnasr; Scott Kaufmann; Andrew D Badley
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

4.  Impact on genetic networks in human macrophages by a CCR5 strain of human immunodeficiency virus type 1.

Authors:  Carter R Coberley; James J Kohler; Joseph N Brown; Joseph T Oshier; Henry V Baker; Michael P Popp; John W Sleasman; Maureen M Goodenow
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  Fibroblast Growth Factor-2 and the HIV-1 Tat Protein Synergize in Promoting Bcl-2 Expression and Preventing Endothelial Cell Apoptosis: Implications for the Pathogenesis of AIDS-Associated Kaposi's Sarcoma.

Authors:  Cecilia Sgadari; Giovanni Barillari; Clelia Palladino; Stefania Bellino; Brunella Taddeo; Elena Toschi; Barbara Ensoli
Journal:  Int J Vasc Med       Date:  2011-10-09

6.  HIV-1 Tat protein enhances microtubule polymerization.

Authors:  Jean de Mareuil; Manon Carre; Pascale Barbier; Grant R Campbell; Sophie Lancelot; Sandrine Opi; Didier Esquieu; Jennifer D Watkins; Charles Prevot; Diane Braguer; Vincent Peyrot; Erwann P Loret
Journal:  Retrovirology       Date:  2005-02-03       Impact factor: 4.602

Review 7.  Anti-apoptotic mechanisms of HIV: lessons and novel approaches to curing HIV.

Authors:  Nathan W Cummins; Andrew D Badley
Journal:  Cell Mol Life Sci       Date:  2012-12-30       Impact factor: 9.261

8.  Drug-induced reactivation of apoptosis abrogates HIV-1 infection.

Authors:  Hartmut M Hanauske-Abel; Deepti Saxena; Paul E Palumbo; Axel-Rainer Hanauske; Augusto D Luchessi; Tavane D Cambiaghi; Mainul Hoque; Michael Spino; Darlene D'Alliessi Gandolfi; Debra S Heller; Sukhwinder Singh; Myung Hee Park; Bernadette M Cracchiolo; Fernando Tricta; John Connelly; Anthony M Popowicz; Richard A Cone; Bart Holland; Tsafi Pe'ery; Michael B Mathews
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.